PDE9A Assay Kit

Phosphodiesterases (PDEs) play an important role in dynamic regulation of cAMP and cGMP signaling. PDE9A is primarily expressed in spleen, small intestine, and brain. PDE9 inhibitors have been studied as therapeutics for treatment of cardiovascular diseases, diabetes, and neurodegenerative disorders. The PDE9A Assay Kit is designed for identification of PDE9A inhibitors using fluorescence polarization. The assay is based on the binding of a fluorescent nucleotide monophosphate generated by PDE9A to the binding agent. The PDE9A inhibitor screening assay kit comes in a convenient 96-well format, including purified PDE9A enzyme, fluorescently labeled PDE9 substrate (cGMP), binding agent, and PDE assay buffer for 100 enzyme reactions. The key to the PDE9A Assay Kit is the specific binding agent. Using this kit, only two simple steps on a microtiter plate are required for PDE9A reactions. First, the fluorescently labeled cGMP is incubated with a sample containing PDE9A for 1 hour. Second, a binding agent is added to the reaction mix to produce a change in fluorescent polarization that can then be measured using a fluorescence reader.